Trials / Recruiting
RecruitingNCT06029998
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
A Phase II Study of Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion. The main question\[s\] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants. Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle is about 21 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | sub-cutaneous injection of bortezomib for 6-8 cycles of treatment. |
Timeline
- Start date
- 2024-03-11
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2023-09-08
- Last updated
- 2025-11-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06029998. Inclusion in this directory is not an endorsement.